Jason Mouabbi

7PUBLICATIONS
23CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 22, 2026
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

|Jan 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava

|Dec 09, 2023
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.

Jason A Mouabbi, Wei Qaio, Yu Shen

|Dec 20, 2022
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies.

Jason A Mouabbi, Akshara Singareeka Raghavendra, Roland L Bassett

|Mar 29, 2022
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Jason A Mouabbi, Amy Hassan, Bora Lim

|Sep 13, 2021
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.

Jason A Mouabbi, C Kent Osborne, Rachel Schiff

Pageof 2

Frequent Collaborators

3 joint publications

Debu Tripathy

2 joint publications

Funda Meric-Bernstam

2 joint publications

Rashmi Murthy

2 joint publications

Paula R Pohlmann